



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,543	10/28/2005	Jaewhan Song	0002204USU/4105	4798
27623 7590 12/15/2009 OHLANDT, GREELEY, RUGGIERO & PERLE, LLP ONE LANDMARK SQUARE, 10TH FLOOR STAMFORD, CT 06901				
EXAMINER				
SAJJADI, FEREDOUN GHOTB				
ART UNIT		PAPER NUMBER		
1633				
MAIL DATE		DELIVERY MODE		
12/15/2009		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/531,543

**Applicant(s)**

SONG ET AL.

**Examiner**

FEREYDOUN G. SAJJADI

**Art Unit**

1633

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 19 August 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) 4-13 and 17-21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3, 14-16 and 22-24 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-06)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

#### ***Claim Status***

This action is in response to papers filed August 19, 2009. Applicant's response to species restriction requirement of May 15, 2009 has been entered. No claims have been amended, cancelled, or newly added. Applicants' species election of suspending agent, suspension and ampoule as a single dosage form, (with traverse) is acknowledged. Claims 1-24 are pending in the application. Claims 4-13 and 17-21, stand withdrawn from further consideration, with traverse, as drawn to non-elected inventions.

Applicants' arguments that the search of one species mandates the search for each of the other species, have been fully considered, but are not found persuasive. In response, it is noted that the search of one species is not co-extensive with the search for the other species. For example the search for a suspension will not result in the discovery for a wafer for example. Thus, the species restriction is deemed proper, maintained and made Final. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144). See MPEP § 821.01. The claims have been examined commensurate with the elected species.

Claims 1-3, 14-16 and 22-24 are under current examination.

#### ***Withdrawn Objections to the Specification***

The brief description for Figures 8 and 17 was objected to in the previous Office action dated November 7, 2008. Applicants have amended the specification, obviating the ground of objection. Thus, the rejection is hereby withdrawn.

#### ***Withdrawn Claim Rejections - 35 USC § 102***

Claims 1-3 and 14-16 were rejected under 35 U.S.C. 102(b) as being anticipated by GenBank Accession No: AF068223 (April 1, 2000), in the previous Office action dated

November 7, 2008. Applicants have amended base claim 1 to include the limitation for a pharmaceutically acceptable carrier, not taught by the cited reference. Thus, the rejection is hereby withdrawn. Applicants' arguments are rendered moot in view of the withdrawn rejection. The claims are however subject to a new rejection over the prior art, as set forth below.

***New Claim Rejection - 35 USC § 103***

Applicants' claim amendments have necessitated the following new ground of rejection.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-3, 14-16 and 22-24 are newly rejected under 35 U.S.C. 103(a) as being unpatentable over GenBank Accession No: AF068223 (April 1, 2000), in view of (U.S. Patent No.: 5,948,883; Sep. 7, 1999).

The claims encompass a composition comprising a Jab1 (Jun-activation binding protein 1) having an amino acid sequence of SEQ ID NO: 2, and encoded by a nucleotide sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.

It should be noted that a pharmaceutically acceptable carrier includes sterile water or a buffer solution. It should further be noted that the claims state the intended use of the composition as a composition for treating or preventing a flavivirus infection. However, a preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to

stand alone. See *In re Hirao*, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and *Kropa v. Robie*, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 1951). If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention's limitations, then the preamble is not considered a limitation and is of no significance to claim construction. *Pitney Bowes, Inc. v. Hewlett-Packard Co.*, 182 F.3d 1298, 1305, 51 USPQ2d 1161, 1165 (Fed. Cir.1999). See also *Rowe v. Dror*, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997) ("where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation"). Accordingly, claims 14-16 are not accorded any patentable weight, as they recite limitations regarding the intended use of the composition.

A Jab1 protein having an amino acid sequence of SEQ ID NO: 2 is taught by GenBank sequence submission AF068223 (limitation of claim 2). The protein is encoded by the nucleotide sequence additionally disclosed (nucleotide positions 22-1282 correspond to SEQ ID NO: 1; limitation of claim 3). GenBank accession No: AF068223 further identifies the sequences as that of Jab1 (limitation of claim 1).

If a prior art structure is capable of performing the intended use as recited in the preamble, then it meets the claim. See, e.g., *In re Schreiber*, 128 F.3d 1473, 1477, 44 USPQ2d 1429, 1431 (Fed.Cir. 1997). "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition patentably new to the discoverer." *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977).

While the protein or nucleic acid encoding Jab1 is not disclosed as suspended in a pharmaceutically acceptable buffer, the suspension of proteins involved in cellular signal transduction was known in the prior art.

Yoshida et al. describe transcription factor proteins that may serve as therapeutics (Title and Abstract), and regulate the c-Jun/AP-1 transcription factor (column 1, lines 35-37); further

disclosing pad1, as a homolog of Jab1, an activator of the jun family transcription factors (column 1, lines 47-51). Yoshida et al. state that the proteins of their invention may be used as drugs (column 15), for treating diseases that include viral infections (column 16), in the form of injectable preparations such as aseptic solutions or suspensions in water or other pharmaceutically acceptable solutions for parenteral administration, in a unit dosage (column 16, lines 20-33). Yoshida et al. further state that the injectable preparation is normally filled in a suitable ampoule (column 16, lines 66-67). Further, preparation of ampules as single dosages was common in the prior art.

Therefore, it would have been *prima facie* obvious for a person of ordinary skill in the art, to suspend the Jab1 protein in a pharmaceutically acceptable carrier, as instantly claimed, with a reasonable expectation of success, at the time of the instant invention. A person of ordinary skill in the art would have been motivated to suspend the Jab1 protein in a pharmaceutically acceptable carrier, because such was expressly taught by Yoshida et al.

### ***Conclusion***

#### **No claims are allowed.**

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. The claims are drawn to the same invention claimed earlier in the application and would have been finally rejected on the grounds and art of record in the next Office Action if they had been entered earlier in the application. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR § 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to FEREYDOUN G. SAJJADI whose telephone number is (571)272-3311. The examiner can normally be reached on 6:30 AM-3:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Fereydoun G Sajjadi/  
Primary Examiner, Art Unit 1633